|
|
|
You can get e-magazine links on WhatsApp. Click here
|
|
|
|
|
|
ClonBio Foods to build commercial-scale fibre facility
|
|
Monday, 29 June, 2026, 08 : 00 AM [IST]
|
|
Dublin, Ireland
|
ClonBio Foods will build a commercial-scale production facility for FibAX, its native corn arabinoxylan fibre, at the company’s site in Dunaföldvár, Hungary. The investment will bring a fibre with differentiated gut health benefits to the global market at commercial scale after eight years of development, and the facility is expected to be operational in the second quarter of 2027.
The new facility will be dedicated to producing fibres from grains, with FibAX as its first product. The facility represents an expansion of its foods’ Dunaföldvár ingredient production campus, which is already home to the company's PurusPro barley protein operation. Its currently makes the fibre at pilot scale, and the new facility will allow the company to produce it at commercial volumes for the first time.
FibAX is a high-molecular-weight corn arabinoxylan, a prebiotic dietary fibre made up of arabinose and xylose molecules. It isolates the fibre intact from the cell wall of the grain, preserving its natural length and native branched structure, which is why the company describes FibAX as a native fibre. This unique structure determines how FibAX is fermented by the gut microbiota and helps explain its slow, sustained activity in the gut.
Enda Ryan, CEO of ClonBio Foods, said, “Arabinoxylan fibres have been studied for years and the science behind them is strong, but nobody has produced them at commercial scale in their native form. We have spent years working out how to make this fibre consistently and at high quality, and this facility takes it from a research-stage ingredient to one that brands can build premium products around. Moving to commercial scale lets us supply the volumes demanded by premium brands and products alike. For these premium brands developing gut health products, one of the biggest advantages is that FibAX delivers meaningful metabolic activity at a low dose. That gives formulators more flexibility while still supporting the gut health outcomes consumers are looking for.”
|
|
|
|
|
|
|
|
|
|